Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 11/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | HRH2 | P25021 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | HRH1 | P35367 | 1/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.68 |
| ▸ | HTR5A | P47898 | 1/20 | 0.68 |
| ▸ | HTR6 | P50406 | 1/20 | 0.68 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.68 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.68 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15131194 | 1.00 | CASR (0.71) | CASRSIGMAR1HTR1AADRA2BADRA2C | |
| SCHEMBL6081570 | 1.00 | CASR (0.71) | CASRSIGMAR1HTR1AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL1179256 | 0.99 | CASR (0.70) | CASRSIGMAR1HTR1AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL1179260 | 0.99 | CASR (0.70) | CASRSIGMAR1HTR1AADRA2BADRA2C | |
| SCHEMBL6221298 | 0.96 | CASR (0.69) | CASRSIGMAR1HTR1AADRA2BADRA2C | |
| SCHEMBL7383150 | 0.96 | CASR (0.69) | CASRSIGMAR1HTR1AADRA2BADRA2C | |
| SCHEMBL15131034 | 0.89 | SIGMAR1 (0.59) | CASRSIGMAR1HTR1AADRA2BADRA2C | |
| SCHEMBL8175405 | 0.88 | CASR (0.62) | CASRSIGMAR1HTR1AADRA2BADRA2C | |
| SCHEMBL31424070 | 0.88 | CASR (0.62) | CASRSIGMAR1HTR1AADRA2BADRA2C | |
| SCHEMBL7963841 | 0.88 | CASR (0.62) | CASRSIGMAR1HTR1AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054169-A1 | COMPOSITIONS AND METHODS FOR TOPICAL TREATMENT | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | NPS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20060229470-A1 | Calcium receptor-active molecules | NPS PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| US-6313146-B1 | CAN BE USED FOR THERAPY OF DISEASES OR DISORDERS IN A PATIENT BY MODULATING ONE OR MORE INORGANIC ION RECEPTOR ACTIVITIES | NPS PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-0873298-A4 | CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES | NPS PHARMA INC (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0873298-A4 | CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES | NPS PHARMA INC (US) | 2000-05-17 | — | — | EP | disclosed |
| US-6031003-A | TREATING A PATIENT HAVING A DISEASE OR DISORDER TREATABLE BY MODULATING ACTIVITY OF CALCIUM RECEPTORS IN VITRO BY ADMINISTERING A CALCIMIMETIC COMPOUND DETERMINED BY THE CALCILYTIC BOVINE PARATHYROID CELL TEST; OSTEOPOROSIS | NPS PHARMACEUTICALS, INC. (US) | 2000-02-29 | — | — | US | disclosed |
| US-6011068-A | CARBOCYCLIC-ALKYL SECONDARY AMINES | NPS PHARMACEUTICALS, INC. (US) | 2000-01-04 | — | — | US | disclosed |
| US-5962314-A | CERTAIN CELLS IN THE BODY RESPOND NOT ONLY TO CHEMICAL SIGNALS, BUT ALSO TO IONS SUCH AS EXTRACELLULAR CALCIUM IONS (CA.SUP.2+). THE INVENTION RELATES TO NUCLEIC ACIDS ENCODING SUCH RECEPTORS AND CELLS CONTAINING SUCH NUCLEIC ACIDS. | NPS PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5858684-A | CONTACTING RECOMBINANT CELL WITH TEST COMPOUND WHICH IS NOT VERAPAMIL OR GALLOPAMIL, DETERMINING ABILITY OF COMPOUND TO AFFECT ACTIVITIES OF INORGANIC ION RECEPTOR; DETERMINATION OF AGONIST AND ANTAGONIST DRUGS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0873298-A1 | CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES | NPS PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
| EP-0873298-A1 | CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES | NPS PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5763569-A | POLYPEPTIDES AS CALCIUM RECEPTORS TO GENERATE ANTIBODIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC (US) | 1998-06-09 | — | — | US | disclosed |
| US-5688938-A | Calcium receptor-active molecules | THE BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 1997-11-18 | — | — | US | disclosed |
| US-5648541-A | FORMING ENANTIOMERS FROM IMINES BY REDUCTION WITH LITHIUM ALUMINUM HYDRIDE | NPS PHARMACEUTICALS, INC. (US) | 1997-07-15 | — | — | US | disclosed |
| WO-1997011934-A1 | CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES | NPS PHARMACEUTICALS, INC. (US) | 1997-04-03 | — | — | WO | disclosed |
| WO-1997011934-A1 | CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES | NPS PHARMACEUTICALS, INC. (US) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229470-A1 | Calcium receptor-active molecules | CASR, CALCR, ORAI1 | CASR 1/4885SIGMAR1 708/4885HTR1A 3316/4885 |
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | CASR, CALCR, ORAI1 | CASR 1/4885SIGMAR1 708/4885HTR1A 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.